Insights into antitrypanosomal drug mode-of-action from cytology-based profiling - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue PLoS Neglected Tropical Diseases Année : 2018

Insights into antitrypanosomal drug mode-of-action from cytology-based profiling

Résumé

Chemotherapy continues to have a major impact on reducing the burden of disease caused by trypanosomatids. Unfortunately though, the mode-of-action (MoA) of antitrypanosomal drugs typically remains unclear or only partially characterised. This is the case for four of five current drugs used to treat Human African Trypanosomiasis (HAT); eflornithine is a specific inhibitor of ornithine decarboxylase. Here, we used a panel of T. brucei cellular assays to probe the MoA of the current HAT drugs. The assays included DNA-staining followed by microscopy and quantitative image analysis, or flow cytometry; terminal dUTP nick end labelling to monitor mitochondrial (kinetoplast) DNA replication; antibody-based detection of sites of nuclear DNA damage; and fluorescent dye-staining of mitochondria or lysosomes. We found that melarsoprol inhibited mitosis; nifurtimox reduced mitochondrial protein abundance; pentamidine triggered progressive loss of kinetoplast DNA and disruption of mitochondrial membrane potential; and suramin inhibited cytokinesis. Thus, current antitrypanosomal drugs perturb distinct and specific cellular compartments, structures or cell cycle phases. Further exploiting the findings, we show that putative mitogen-activated protein-kinases contribute to the melarsoprol-induced mitotic defect, reminiscent of the mitotic arrest associated signalling cascade triggered by arsenicals in mammalian cells, used to treat leukaemia. Thus, cytology-based profiling can rapidly yield novel insight into antitrypanosomal drug MoA.
Fichier principal
Vignette du fichier
pntd.0006980.pdf (2.06 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

pasteur-03107158 , version 1 (12-01-2021)

Licence

Identifiants

Citer

James Thomas, Nicola Baker, Sebastian Hutchinson, Caia Dominicus, Anna Trenaman, et al.. Insights into antitrypanosomal drug mode-of-action from cytology-based profiling. PLoS Neglected Tropical Diseases, 2018, 12 (11), pp.e0006980. ⟨10.1371/journal.pntd.0006980⟩. ⟨pasteur-03107158⟩

Collections

PASTEUR
23 Consultations
70 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More